Researches advance on anti-VEGF medication for retinopathy of prematurity
Retinopathy ofprematurity(ROP)is one of the major cause of childhood blindness worldwide. Previously, the treatment for ROP for the patients at the threshold period and before high-risk period is mainly the retinal laser and cryotherapy. However, cryotherapy and laser therapy are destructive, which...
Main Authors: | Huan-Huan Zhao, Xue-Lin Huang, Su-Zhen Xie, Chao-Hui Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2013-12-01
|
Series: | Guoji Yanke Zazhi |
Subjects: | |
Online Access: | http://www.ies.net.cn/cn_publish/2013/12/201312016.pdf |
Similar Items
-
Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy
by: Wang H
Published: (2016-05-01) -
Expression of Total Vascular Endothelial Growth Factor and the Anti-angiogenic VEGF 165 b Isoform in the Vitreous of Patients with Retinopathy of Prematurity
by: Min Zhao, et al.
Published: (2015-01-01) -
Anti-VEGF therapy in retinopathy of prematurity
by: Qin Peng, et al.
Published: (2020-11-01) -
The progress of prophylactic treatment in retinopathy of prematurity
by: Hong-Bing Zhang, et al.
Published: (2018-05-01) -
Clinical Course and Results of Anti-VEGF Therapy of Retinopathy of Prematurity
by: L. A. Katargina, et al.
Published: (2021-04-01)